Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
Abstract
1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Puerto, M.; Borson-Chazot, F.; Tabarin, A. Updates on therapy for medullary thyroid cancer in 2021. Ann. Endocrinol. 2021, 83, 114–118. [Google Scholar] [CrossRef] [PubMed]
- Pelizzo, M.; Boschin, I.M.; Bernante, P.; Toniato, A.; Piotto, A.; Pagetta, C.; Nibale, O.; Rampin, L.; Muzzio, P.; Rubello, D. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur. J. Surg. Oncol. 2007, 33, 493–497. [Google Scholar] [CrossRef] [PubMed]
- Kebebew, E.; Ituarte, P.H.; Siperstein, A.E.; Duh, Q.Y.; Clark, O.H. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000, 88, 1139–1148. [Google Scholar] [CrossRef]
- Davi, M.V.; Cosaro, E.; Piacentini, S.; Reimondo, G.M.; Albiger, N.; Arnaldi, G.; Faggiano, A.; Mantovani, G.; Fazio, N.; Piovesan, A.; et al. Prognostic factors in ectopic Cushing’s syndrome due to neuroendocrine tumors: A multicenter study. Eur. J. Endocrinol. 2017, 176, 453–461. [Google Scholar] [CrossRef] [PubMed]
- Moura, M.M.; Cavaco, B.; Pinto, A.; Domingues, R.; Santos, J.R.; Cid, M.O.; Bugalho, M.J.; Leite, V. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br. J. Cancer 2009, 100, 1777–1783. [Google Scholar] [CrossRef] [PubMed]
- Barbosa, S.L.-S.; Rodien, P.; Leboulleux, S.; Niccoli-Sire, P.; Kraimps, J.-L.; Caron, P.; Archambeaud-Mouveroux, F.; Conte-Devolx, B.; Rohmer, V.; Endocrines, G.D.D.T. Ectopic Adrenocorticotropic Hormone-Syndrome in Medullary Carcinoma of the Thyroid: A Retrospective Analysis and Review of the Literature. Thyroid 2005, 15, 618–623. [Google Scholar] [CrossRef] [PubMed]
- Koehler, V.F.; Fuss, C.T.; Berr, C.M.; Frank-Raue, K.; Raue, F.; Hoster, E.; Hepprich, M.; Christ, E.; Pusl, T.; Reincke, M.; et al. Medullary thyroid cancer with ectopic Cushing’s syndrome: A multicentre case series. Clin. Endocrinol. 2021, 96, 847–856. [Google Scholar] [CrossRef] [PubMed]
- Valassi, E.; Santos, A.; Yaneva, M.; Toth, M.; Strasburger, C.J.; Chanson, P.; Wass, J.A.H.; Chabre, O.; Pfeifer, M.; Feelders, R.A.; et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 2011, 165, 383–392. [Google Scholar] [CrossRef] [PubMed]
- Sheikh-Ali, M.; Krishna, M.; Lloyd, R.; Smallridge, R.C. Predicting the development of Cushing’s syndrome in medullary thyroid cancer: Utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization. Thyroid 2007, 17, 631–634. [Google Scholar] [CrossRef] [PubMed]
- von Mach, M.A.; Kann, P.; Piepkorn, B.; Bruder, S.; Beyer, J. Cushing’s syndrome caused by paraneoplastic ACTH secretion 11 years after occurence of a medullary thyroid carcinoma. Dtsch. Med. Wochenschr. 2002, 127, 850–852. [Google Scholar] [CrossRef] [PubMed]
- Nagy-Mignotte, H.; Shestaeva, O.; Vignoud, L.; Guillem, P.; Ruckly, S.; Chabre, O.; Sakhri, L.; Duruisseaux, M.; Mousseau, M.; Timsit, J.-F.; et al. Prognostic Impact of Paraneoplastic Cushing’s Syndrome in Small-Cell Lung Cancer. J. Thorac. Oncol. 2014, 9, 497–505. [Google Scholar] [CrossRef] [PubMed]
- Valassi, E.; Tabarin, A.; Brue, T.; Feelders, R.A.; Reincke, M.; Netea-Maier, R.; Toth, M.; Zacharieva, S.; Webb, S.M.; Tsagarakis, S.; et al. High mortality within 90 days of diagnosis in patients with Cushing’s syndrome: Results from the ERCUSYN registry. Eur. J. Endocrinol. 2019, 181, 461–472. [Google Scholar] [CrossRef] [PubMed]
- Ragnarsson, O.; Olsson, D.S.; Papakokkinou, E.; Chantzichristos, D.; Dahlqvist, P.; Segerstedt, E.; Olsson, T.; Petersson, M.; Berinder, K.; Bensing, S.; et al. Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. J. Clin. Endocrinol. Metab. 2019, 104, 2375–2384. [Google Scholar] [CrossRef] [PubMed]
- Ntali, G.; Asimakopoulou, A.; Siamatras, T.; Komninos, J.; Vassiliadi, D.; Tzanela, M.; Tsagarakis, S.; Grossman, A.B.; Wass, J.A.H.; Karavitaki, N. Mortality in Cushing’s syndrome: Systematic analysis of a large series with prolonged follow-up. Eur. J. Endocrinol. 2013, 169, 715–723. [Google Scholar] [CrossRef] [PubMed]
- Maxwell, J.E.; Sherman, S.K.; O’Dorisio, T.M.; Howe, J.R. Medical management of metastatic medullary thyroid cancer. Cancer 2014, 120, 3287–3301. [Google Scholar] [CrossRef] [PubMed]
- Wijewardene, A.A.; Glastras, S.J.; Learoyd, D.L.; Robinson, B.G.; Tsang, V.H.M. ACTH-secreting medullary thyroid cancer: A case series. Endocrinol. Diabetes Metab. Case Rep. 2017, 2017, 16–0110. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ciampi, R.; Romei, C.; Ramone, T.; Prete, A.; Tacito, A.; Cappagli, V.; Bottici, V.; Viola, D.; Torregrossa, L.; Ugolini, C.; et al. Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing. iScience 2019, 20, 324–336. [Google Scholar] [CrossRef] [PubMed]
- Wirth, L.J.; Sherman, E.; Robinson, B.; Solomon, B.; Kang, H.; Lorch, J.; Worden, F.; Brose, M.; Patel, J.; Leboulleux, S.; et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N. Engl. J. Med. 2020, 383, 825–835. [Google Scholar] [CrossRef] [PubMed]
- Berr, C.M.; Di Dalmazi, G.; Osswald, A.; Ritzel, K.; Bidlingmaier, M.; Geyer, L.L.; Treitl, M.; Hallfeldt, K.; Rachinger, W.; Reisch, N.; et al. Time to recovery of adrenal function after curative surgery for Cushing’s syndrome depends on etiology. J. Clin. Endocrinol. Metab. 2015, 100, 1300–1308. [Google Scholar] [CrossRef] [PubMed]
- Forde, H.E.; Mehigan-Farrelly, N.; Ryan, K.; Moran, T.; Greally, M.; Duffy, A.G.; Byrne, M.M. Metastatic medullary thyroid carcinoma presenting as ectopic Cushing’s syndrome. Endocrinol. Diabetes Metab. Case Rep. 2021, 2021, 20–0207. [Google Scholar] [CrossRef]
- Agosto, S.S.V.; Zhu, E.; Nguyen, M.; Kherani, J.; Olek, E.; Rothenberg, S.M.; Kane, M.; Sherman, S.I. Successful resolution of Cushing syndrome due to ectopic ACTH syndrome in metastatic medullary thyroid carcinoma during treatment with selpercatinib (LOXO-292), a novel highly selective RET inhibitor. In Proceedings of the 89th Annual Meeting American Thyroid Association, Chicago, IL, USA, 30 October–3 November 2019. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ragnarsson, O.; Piasecka, M.; Hallqvist, A. Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Curr. Oncol. 2022, 29, 3494-3498. https://doi.org/10.3390/curroncol29050282
Ragnarsson O, Piasecka M, Hallqvist A. Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Current Oncology. 2022; 29(5):3494-3498. https://doi.org/10.3390/curroncol29050282
Chicago/Turabian StyleRagnarsson, Oskar, Marta Piasecka, and Andreas Hallqvist. 2022. "Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer" Current Oncology 29, no. 5: 3494-3498. https://doi.org/10.3390/curroncol29050282
APA StyleRagnarsson, O., Piasecka, M., & Hallqvist, A. (2022). Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Current Oncology, 29(5), 3494-3498. https://doi.org/10.3390/curroncol29050282